MARTINEZ, Calif.–(BUSINESS WIRE)–ExThera Medical Corporation (ExThera) today announced Dr. Stefan
Büttner, a senior staff member of the Department of Nephrology, Dialysis
and Kidney Transplantation at University Hospital Frankfurt, will
present on his clinical experience with the ExThera’s Seraph®
100 Microbind® Affinity Blood Filter (Seraph) at the
International Symposium on Intensive Care and Emergency Medicine
(ISICEM) in Brussels, Belgium on Wednesday, March 20. ExThera, an
early-stage medical technology company in the San Francisco Bay Area, is
a developer of therapies for reducing bacteria and viruses in blood.
During his presentation, entitled Extracorporeal Pathogen
Elimination is on the Horizon, Dr. Büttner will share insights
from his clinical experience using Seraph in the treatment of bacteremia
during dialysis. Dr Büttner is a nephology specialist, clinical
researcher and expert in blood purification techniques, and his
viewpoint is of particular interest due to his experience with
plasmapheresis and the use of extracorporeal therapies for renal
replacement therapy, liver failure and infectious diseases. Dr.
Büttner’s presentation will take place onsite at the Symposium in the
Tent during the Blood Purification session and will run from
4:30-4:45 p.m. local time.
Seraph is designed to reduce the duration and intensity of bloodstream
infections to improve clinical outcomes. It is the first and only
broad-spectrum filter that reduces pathogens in whole blood. By using
immobilized heparin with a unique molecular architecture, Seraph mimics
the heparan sulfate binding sites on endothelial cells that are targeted
by invading pathogens. Seraph’s high surface area quickly reduces large
amounts of drug-resistant and drug-susceptible bacteria, viruses,
toxins, and sepsis mediators in flowing blood.
In its effort to eradicate life-threatening bloodstream infections, and
their progression to sepsis, ExThera is working towards CE Mark approval
and product introduction into the EU in mid-2019.
“The need for advances in the treatment of bloodstream infections have,
until now, gone largely unmet. However, ExThera’s technology has
repeatedly shown promise in preclinical studies and clinical testing as
a safe and effective option,” said Robert Ward, CEO of ExThera. “We’re
excited for the opportunity to educate the medical community at the
important ISICEM meeting about Seraph® through Dr. Büttner’s
experience, and to make it available for use in treating these
infections in the near future.”
About the Seraph® Microbind®Affinity
As a patient’s blood flows through the Seraph Microbind Affinity Blood
Filter, it passes over tiny microspheres coated with molecular receptor
sites that mimic the receptors on human cells that pathogens use when
they invade the body. Harmful substances are quickly captured and
adsorbed onto the surface and are thereby reduced in concentration in
the bloodstream. Seraph does not add anything to the blood, which is
returned to the patient with blood cells intact. The adsorption media is
a flexible platform using chemically-bound, immobilized heparin for its
blood compatibility, and its unique capacity to bind pathogens.
Seraph may be configured with optional supplemental adsorbents to bind
other toxins and evolved pathogens. For example, ‘Seraph 200’ adds
endotoxin binding to Seraph 100, which may be useful in bloodstream
infections that progress to endotoxemia. The Seraph filters have a
blood-contacting surface that is anti-thrombogenic and anti-inflammatory.
About ExThera Medical
Based in Martinez, California, and in Vaals, The Netherlands, ExThera is
a privately held medical device company developing innovative,
single-use blood filters capable of capturing a broad range of bacteria,
viruses, parasites, toxins or other harmful substances from whole blood.
The company develops therapeutic products to treat patients in the
hospital or clinic, during epidemics, or on the battlefield. Led by an
accomplished management team with extensive experience in
blood-contacting devices and biomaterials, the company has strong patent
protection and a growing body of data from independent laboratory
studies, from its participation in DARPA’s Dialysis-Like Therapeutics
program and from a successful EU clinical trial. For more information,
Disclaimer: All information contained in this news release
derives from plausible reliable sources, which, however, have not been
independently examined. There is no warranty, confirmation or guarantee,
and no responsibility or liability is taken concerning correctness or
completeness. As far as it is allowed by the relevant law, no liability
whatsoever is taken on for any direct or indirect loss caused by the
deployment of this news release or its contents. This communication
includes forward-looking statements regarding events, trends and
business prospects that may affect our future operating results and
financial position. Such statements are subject to risks and
uncertainties that could cause our actual results and financial position
to differ materially. The investment and/or the revenues that arise from
it can rise or fall. A total loss is possible. Persons who are in
possession of this news release are requested to obtain information
concerning possible legal limitations and to observe them accordingly.
We assume no responsibility to update or revise any forward-looking
statements contained in this news release to reflect events, trends, or
circumstances after the date of this news release.
Caution: The Seraph® Microbind® Affinity Blood Filter is
currently undergoing clinical evaluation and is not available for
Keith McCrea, Ph.D.
Thank you for donating to DutchNews.nl.
We could not provide the Dutch News service, and keep it free of charge, without the generous support of our readers. Your donations allow us to report on issues you tell us matter, and provide you with a summary of the most important Dutch news each day.Make a donation